CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS
Macaya Douoguih, M.D., MPH, is Head of Clinical Development and Medical Affairs, Vaccines at Janssen. Macaya heads a team of physicians and scientists that lead the clinical development of the viral and bacterial vaccine programs, working closely with the R&D organization towards the goal of licensing three novel best-in-class vaccines by 2025.
Prior to this role, Macaya was the Clinical Franchise Leader for Emerging Diseases, overseeing the clinical development of Janssen’s vaccines portfolio against pathogens of global significance and for bio preparedness, such as Ebola/Filoviruses, Zika, and Polio.
Macaya joined Janssen Vaccines in 2010 as Medical Leader for several vaccine/large molecule programs in Infectious Diseases & Vaccines and was instrumental in leading the accelerated monovalent clinical program for Janssen’s Ebola vaccine during the 2014/2015 outbreak, which initiated 10 concurrent clinical studies.
Before joining the Johnson & Johnson Family of Companies, Macaya led the clinical development of Crucell’s adenovirus-based TB vaccine candidate at Aeras. Earlier she held several positions focused on infectious diseases clinical research and public health.
Macaya has a medical degree from the University of Wisconsin-Madison Medical School and a Master of Public Health from Johns Hopkins Bloomberg School of Public Health.
- Ebola: The Fight Continues Four Years After the Worst Outbreak in History
- An Open Letter on Systemic Racism and Health Disparities
- "AIDS Won’t Stop for COVID-19": Meet 3 Inspiring Women Who Are as Committed as Ever to Making HIV History